The text starts here.

News Release

December 12, 1996

Distribution of "ProHance Injection", Non-ionic MRI Diagnostic Agent, to Be Unified through Eisai

Eisai Co., Ltd. (head office: Tokyo, president: Haruo Naito) and Bristol-Myers Squibb K.K. (head office: Tokyo, president: Hiroji Arai), have agreed both companies will unify distribution of "ProHance Injection", the non-ionic magnetic resonance imaging (MRI) diagnostic agent, through one company, Eisai Co., Ltd., on January 1, 1997 in order to provide, collect and communicate information on the proper use of the agent more efficiently and appropriately.

"ProHance Injection" had been distributed by Bristol-Myers Squibb K.K. since July 1994, and has been distributed by Eisai and Bristol-Myers Squibb K.K. since July 1995 on the basis of one brand through two channels and two promotions.

This unification of distribution will give Eisai a more substantial presence in the area by including the use of MRI contrast media.

The acquisition of Bristol-Myers Squibb Company's contrast media and radiopharmaceuticals business in the US by Bracco S.p.A. in August 1994, prompted Eisai, which has an alliance with Bracco, to begin distribution of the drug.

"ProHance Injection" is the first "non-ionic, macrocyclic" MRI contrast medium in the world, and is characterized by its high stability level.

For more information, please contact:
Takeyuki Uchiyama
Public Relations, Eisai Co., Ltd.
Phone: 03-3817-5120

Kimitoshi Isobe or Keiko Toba
General Administration, Bristol-Myers Squibb K.K.
Phone: 03-5323-8302